Retatrutide

Retatrutide (LY3437943) is an investigational triple agonist that simultaneously activates three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. Developed by Eli Lilly and Company and currently in Phase 3 clinical trials for obesity and type 2 diabetes, retatrutide represents the next evolutionary step beyond tirzepatide's dual GIP/GLP-1 agonism. No triple incretin agonist has previously reached this stage of clinical development, making retatrutide one of the most closely watched compounds in all of metabolic medicine. Its Phase 2 data has already produced numbers that the research community did not consider pharmacologically achievable prior to their publication.

The defining mechanistic feature that distinguishes retatrutide from tirzepatide is the addition of glucagon receptor agonism. Glucagon has long been viewed as an adversarial hormone in the context of metabolic disease — it raises blood glucose by stimulating hepatic glycogenolysis (the breakdown of stored glycogen) and gluconeogenesis (de novo glucose synthesis from amino acid and glycerol substrates). This hyperglycaemic action is precisely why drugs like semaglutide and tirzepatide suppress glucagon as part of their mechanism. However, this is only one side of glucagon's biology. Glucagon receptor activation in adipose tissue and the liver simultaneously drives potent thermogenic effects — increasing energy expenditure and fatty acid oxidation — and lipolytic effects — mobilising stored triglycerides from fat depots. These energy-expenditure and fat-mobilising effects are highly desirable for weight loss, if they can be harnessed without the accompanying hyperglycaemia.

The pharmacological genius of retatrutide's design lies in the simultaneous activation of the GLP-1 receptor, which potently suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. By activating both the glucagon receptor (to drive thermogenesis and lipolysis) and the GLP-1 receptor (to counteract glucagon's hyperglycaemic hepatic effects and provide incretin-mediated insulin stimulation) simultaneously, retatrutide achieves the energetically desirable effects of glucagon receptor activation while neutralising the hyperglycaemic effect that would make glucagon agonism alone untenable in metabolic disease. The addition of GIP receptor co-agonism then layers the established benefits of GIP — complementary insulin secretion stimulation, adipocyte fat metabolism, potential nausea attenuation — onto the already potent GLP-1 and glucagon dual action.

The Phase 2 TRIUMPH trial, published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues, produced results that genuinely shocked the metabolic medicine research community. The trial enrolled 338 participants without diabetes across five dose groups. At the highest dose tested — 12 mg once weekly — participants lost an average of 24.2% of body weight at 48 weeks. This is not a rounding error or an artefact of outlier response; the median weight loss at the highest dose was 22.8%, and the 48-week observation period had not reached a plateau for the highest-dose group, with trajectory modelling suggesting further losses in longer trials. For comparison, average weight loss with Roux-en-Y gastric bypass surgery in most series falls in the 25–30% range — and retatrutide is approaching this benchmark with a weekly subcutaneous injection.

Even at the 4 mg weekly dose — well below the maximum studied — participants lost an average of 17.5% body weight at 48 weeks. This number would have been considered an extraordinary result from any prior pharmacotherapy. At 8 mg, the average was 22.1%. The dose-response relationship was steep and consistent, suggesting the 12 mg dose likely represents a submaximal point on the dose-response curve — longer trials at higher doses, if tolerable, may drive further weight reduction.

The mechanistic basis of retatrutide's superior efficacy over tirzepatide is almost certainly the thermogenic component added by glucagon receptor activation. While GLP-1 and GIP receptor agonism primarily address appetite (reducing caloric intake), glucagon receptor activation increases resting energy expenditure — effectively burning more calories even at rest. This dual action on both sides of the energy balance equation (reduced intake and increased expenditure) is mechanistically unique among currently studied incretin peptides and likely explains the additional 3–4% weight loss advantage observed when comparing Phase 2 retatrutide data to Phase 3 tirzepatide data.

Retatrutide is engineered as a fatty-acid-conjugated peptide for albumin binding and once-weekly subcutaneous administration, with a half-life of approximately 6 days — in the same range as semaglutide and tirzepatide. The GI adverse event profile in the Phase 2 trial was broadly comparable to tirzepatide, with nausea, vomiting, and diarrhoea being dose-limiting in some participants but manageable with standard slow titration. An elevated heart rate was noted in the glucagon-receptor-activated groups, consistent with glucagon's known chronotropic effects, which represents an important safety variable to monitor in Phase 3.

Phase 3 trials for retatrutide in obesity (TRIUMPH-1, TRIUMPH-2) and type 2 diabetes are currently underway with results expected by 2025–2026. If Phase 3 confirms the Phase 2 findings, retatrutide is positioned to become not only the most effective pharmacological anti-obesity treatment ever approved but also potentially the first triple incretin agonist in the clinical toolkit — a watershed moment for metabolic pharmacology.

For the broader research community, retatrutide serves as a proof-of-concept demonstration that each incremental receptor agonism addition — from GLP-1 alone (semaglutide) to GLP-1 + GIP (tirzepatide) to GLP-1 + GIP + glucagon (retatrutide) — appears to provide incrementally greater metabolic benefit. This mechanistic ladder has profound implications for the pipeline of incretin-based therapies and for understanding the redundancy and complementarity of the incretin system in weight regulation.